Announced
Completed
Synopsis
Oriental Fortune Capital, a venture capital firm, led a $100m Series B round in Bao Pharmaceuticals, a biopharmaceutical company, with participation from Haitong Innovation and Guosheng Group-backed Sun Rock Capital. Shanghai-based recombinant protein and antibody drug specialist said that it will use the funds to drive the commercialization of core products in development and key clinical trials for new pipelines.
Show Details & Financials
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.